Documentos relacionados

1. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
2. A small molecule targeting hepatitis B surface antigen inhibits clinically relevant drug-resistant hepatitis B virus.
3. [Analysis of risk factors for drug resistant mutations in the reverse transcriptase region in chronic hepatitis B virus-infected patients].
4. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
5. Reverse transcriptase meets DNA, again: Possible roles for transposable elements in host DNA repair.
6. Sustainable Protocol for the Synthesis of 2',3'-Dideoxynucleoside and 2',3'-Didehydro-2',3'-dideoxynucleoside Derivatives.
7. Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
8. Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
9. L1 drives IFN in senescent cells and promotes age-associated inflammation.
10. Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure.